Inhibrx Biosciences Stock Forecast
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
INBX analyst consensus
Consensus (4 analysts)
none
Avg. price target
$266.67+187.48%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Inhibrx Biosciences (2026-10-08), 3 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $266.67, with a high estimate of $325.00 and a low estimate of $230.00. The average target implies upside of 187.5% from the current price of $92.76.
The spread between the highest and lowest targets is 41.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for INBX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 75% |
| Hold | 1 | 25% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $230.00 | +147.95% |
| Average target | $266.67 | +187.48% |
| High target | $325.00 | +250.37% |